In most of the study patients (95.0%), the primary lesions were solid tumors (Lung, Breast, Stomach, Colon, Uterus, Liver, Prostate, Ovary, Pancreas) and 61.7% had advanced cancer with metastatic lesions and 34 patients had co-administered standard care (mostly chemo)
Hormones activated: GLP-1, GIP, PYY
the placebo group in major acute cardiovascular events, as has recently been shown for cardiovascular outcome trials with the GLP-1 receptor agonists liraglutide (131), semaglutide (132), albiglutide (133) and dulaglutide 2 and the SGLT2 inhibitors empagliflozin (134) and canagliflozin (135)
Moreover, they provide effective body-weight control and may prevent the development of steroid-induced obesity (17)